SBFM Stock UPDATES Sunshine Biopharma (SBFM) 0.1278 08/03/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Sunshine Biopharma (SBFM) 0.1278 $SBFM

Sunshine Biopharma Launches Sunshine Biopharma Canada Inc., a Wholly Owned Canadian Subsidiary in Anticipation of Signing Manufacturing and Commercialization Contracts in Canada
Marketwire - Tue Jul 29, 7:03AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has formed Sunshine Biopharma Canada Inc., a Canadian wholly owned subsidiary for the purposes of conducting pharmaceutical business in Canada and elsewhere around the globe. Sunshine Biopharma anticipates that Sunshine Biopharma Canada will soon sign manufacturing, marketing, sales and distribution contracts for various pharmaceutical and biomedical products. According to various estimates, the worldwide market for generic pharmaceuticals which Sunshine Biopharma Canada is positioning itself to participate in is in excess of $100 billion per year.

Sunshine Biopharma's Adva-27a Featured in 2014 Worldwide Uterine Cancer Report for Its Effectiveness Against Multidrug Resistant Uterine Cancer Cells
Marketwire - Mon Jun 09, 7:03AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that Adva-27a, the Company's flagship oncology drug candidate was featured in Global Markets Direct: Uterine Cancer - Pipeline Review, H1 2014 Report for its effectiveness against multidrug resistant uterine cancer cells in vitro.

Research and Markets: Worldwide Uterine Cancer Pipeline Report 2014 featuring Azaya Therapeutics Incorporated, EndoCeutics & Sunshine Biopharma
Business Wire - Wed May 28, 2:09PM CDT
Research and Markets (http://www.researchandmarkets.com/research/9bk98l/uterine_cancer) has announced the addition of the "Uterine Cancer - Pipeline Review, H1 2014" report to their offering.

Worldwide Uterine Cancer Pipeline Report 2014 featuring Azaya Therapeutics Incorporated, EndoCeutics & Sunshine Biopharma
M2 - Wed May 28, 10:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9pvjg8/uterine_cancer) has announced the addition of the "Uterine Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Uterine Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uterine Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Azaya Therapeutics Incorporated - EndoCeutics, Inc. - Sunshine Biopharma, Inc. For more information visit http://www.researchandmarkets.com/research/9p...ine_cancer

Management of Sunshine Biopharma Alarmed by the Recent World Health Organization Report That Cancer Is on the Rise
Marketwire - Mon Mar 31, 7:03AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, has issued a response to the recently released reports by the World Health Organization and the Pancreatic Cancer Action Network.

Jang Attributes Peaceful Council Elections to Security Arrangements
by Seriki Adinoyi - All Africa Global Media - Wed Feb 26, 1:34AM CST
Governor Jonah Jang of Plateau State has attributed the peaceful conduct of the local government area elections in the state to the adequate security measures put in place for the exercise.

Sunshine Biopharma Begins Construction of Mouse Xenograft Models for Pancreatic Cancer to Advance Adva-27a as a Treatment for This Deadly Form of Cancer
Marketwire - Fri Feb 14, 7:00AM CST
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has initiated the construction of mouse xenograft models for pancreatic cancer as part of the plans of positioning Adva-27a for clinical development for pancreatic cancer in parallel with multidrug resistant breast cancer. The work is being conducted in collaboration with Sunshine Biopharma's parent company, Advanomics Corporation, the co-recipient of $1.45 million in research grants in Canada. As previously announced (see press release dated June 4, 2013), Adva-27a, a Topoisomerase II inhibitor, was found to be effective at destroying cells of the very aggressive pancreatic cancer cell line, Panc-1.

Sunshine Biopharma Continues Its Efforts to Re-Domicile in Canada for Business Expansion and Financing Opportunities for Adva-27a Cancer Drug Candidate
Marketwire - Tue Feb 04, 7:04AM CST
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of proprietary drugs for the treatment of various forms of cancer, today announced that it is continuing its efforts to re-domiciling the Company in Canada in order to capitalize on management's belief that by doing so, the Company will generate additional business expansion opportunities and gain access to financing programs available to Canadian corporations. On January 31, 2014, the Company filed an S-4 Registration Statement wherein it is attempting to re-domicile to Canada from Colorado.

Sunshine Biopharma Targets Pancreatic Cancer as Second Indication for Clinical Trials of Adva-27a Compound
Marketwire Canada - Tue Jan 21, 7:08AM CST
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it is now targeting pancreatic cancer as a second indication for Adva-27a, the Company's flagship anticancer drug candidate. As previously announced (see press release dated June 4, 2013), Adva-27a, a Topoisomerase II inhibitor, was found to be effective at destroying cells of the very aggressive pancreatic cancer cell line, Panc-1. Adva-27a was able to kill these cells with an IC50 of approximately 4 micromolar, a pharmacologically very favorable drug concentration. Based on initial data, the Company is moving forward with intentions to conduct a Phase I clinical trial of Adva-27a for pancreatic cancer in parallel to the planned Phase I clinical trial of Adva-27a for breast cancer that is scheduled to be hosted at McGill University's Jewish General Hospital in Montreal.

Galectin Shares Rise on IND Filing, is Sunshine Biopharma Next in Line?
ACCESSWIRE - Wed Sep 18, 7:21AM CDT
Drug development is a business that can be a minefield; littered with pieces of failed companies that couldn't manage expenses and compounds that failed to meet expectations. The beauty of biotechnology, though, is a level playing field in which companies can grow robust valuations based upon target indications and assets, even at early stages of development. With initiatives around the world to expedite the regulatory pathway and major pharmaceutical companies hungry for acquisitions, there probably isn't a better time to be looking at some well-positioned up-and-comers in the space.

OTC Daily Alert Stock Watch - Sunshine Biopharma Inc., (OTCQB: SBFM)
WorldStockWire - Wed Sep 11, 10:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

Sunshine Biopharma Parent Company Acquires Garmen Laboratories, a Certified GMP Manufacturing Lab
Marketwire - Mon Aug 26, 7:01AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announces that its parent company, Advanomics Corporation, has signed a binding agreement to acquire Garmen Laboratories (Laboratoires Garmen Inc.), a Good Manufacturing Practices (GMP) laboratory with 45 employees providing complete pharmaceutical manufacturing and testing services to a broad range of industrial, institutional and governmental agencies. A profitable company, Garmen Laboratories is headquartered in a 50,000-square-foot, state-of-the-art facility in Montreal, Canada. With nearly 35 years of industry experience, Garmen delivers an array of solutions that can help detect, identify and quantify trace-level chemical components in the nutraceutical, food and pharmaceutical industries.

Sunshine Biopharma Parent Company Receives $510,000 Research Grant for Adva-27a Cancer Drug Candidate, Brings Total to $1.45 Million
Marketwire - Mon Aug 12, 7:01AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that its parent company, Advanomics Corporation, has been awarded a second research grant, this time from Canadian Institutes of Health Research (CIHR), to advance the development of Adva-27a, the Company's flagship anticancer drug candidate in development for multidrug resistant cancers. The grant, in the amount of $510,000, was awarded to Advanomics Corporation in collaboration with Ecole Polytechnique.



Scroll down for more posts ▼

Top 10 Most Recent News Articles

Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 168

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 128

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 224

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 142

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 214

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 114

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 196

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 175

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 211

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading

Top 5 Most Recently Viewed Articles

Merit Medical Systems: Price Target Raised Amid Strong Growth Prospects

Updated Category News Views 92

Merit Medical Systems Price Target Increased by Baird Baird has enhanced its price target for Merit Medical Systems, Inc. (NASDAQ: MMSI) from $96.00 to $107.00, keeping an Outperform rating on the stock. This adjustment anticipates that the company will surpass its organic growth rate and earnings per share (EPS) expectations for the upcoming quarter. Confidence in Future...

Continue Reading
Qualifacts Is Enhancing Collaborative Workspaces in Tampa

Updated Category News Views 122

Qualifacts Consolidates Tampa Operations into a Modern Office Qualifacts, a prominent player in the field of electronic health records (EHR) and data solutions tailored for behavioral health and human services organizations, has made a significant move by consolidating its two smaller offices in Tampa. The company has transitioned into a new, modern location designed to...

Continue Reading
Unlocking the Potential of Neuromarketing for Digital Strategies

Updated Category News Views 140

Understanding Neuromarketing and Its Impact In today's competitive landscape, businesses are continuously seeking ways to enhance their digital marketing strategies. One approach gaining momentum is neuromarketing, which delves into the psychology behind user behavior. A recent article from Digital Silk explores how neuromarketing principles can guide organizations in...

Continue Reading
Monkee's of Loudoun Opens to Cheers and Elegance

Updated Category News Views 187

Bringing Southern Charm to Loudoun We've all seen those places where people parade in with snooty airs and pricetags that could feed a family for a week, but this one feels different. Monkee’s of Loudoun isn’t just rolling in the racks of high fashion — it’s bringing the allure of the South with a sprinkle of luxury and empathy. This franchise is no amateur,...

Continue Reading
PG&E Critiques Senate Bill 492's Wildfire Solutions

Updated Category News Views 60

PG&E's Take on Senate Bill 492: More to Be Desired Sit down for a moment, because PG&E's not mincing words with their latest statement. Talking about Senate Bill 492, PG&E puts it plain and clear—this legislation is just skirting around the edges of what's really needed to tackle California's wildfire crisis. In their eyes, it's like putting a band-aid on a wound that...

Continue Reading